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Purpose of the study
The aim of the Rainbow Cohort is to assess the tolerability
and efficacy of initiating treatment with, or switching
treatment to saquinavir (SQV) 500 mg film-coated tablet
formulation. We present the final 48-week subgroup anal-
ysis of antiretroviral therapy (ART)-naïve patients.
Methods
Multicenter, prospective, open-label, observational
cohort study. Tolerability assessments include changes in
liver enzymes and lipid levels from baseline to week 48,
efficacy assessments include changes in viral load (VL)
and CD4 count.
Summary of results
48-week analysis of n = 275 ART-naïve patients. Baseline
characteristics: 83% male, median age 39 years, median
time since HIV diagnosis 1 year (IQR 0; 4), median base-
line viral load (VL) 115,781 HIV-RNA cp/mL (IQR
35,375; 347,450), median CD4 count 200 cells/mm3
(IQR 89; 297). Antiretroviral regimen included SQV/r
plus tenofovir/emtricitabine, zidovudine/lamivudine or
abacavir/lamivudine in 49%, 19% and 7% of patients,
respectively.
In week 48, the proportion of patients achieving a VL <50
cp/mL was 75.3% (OT analysis) and 67.3% (ITT, LOCF
analysis), respectively. Median increase in CD4 cell count
was + 174 cells/mm3 (IQR 86; 265). Median changes in
triglycerides, total cholesterol, ALT, AST and γ-GT were
+17 mg/dL (IQR -27; 71), +27 mg/dL (4; 55), -6 U/L (-26;
1), -1 U/L (-9; 6), -2 U/L (-25; 6), respectively. SQV treat-
ment was stopped in 21% of the patients (3% due to side-
effects, 1% due to virologic failure). See Figure 1.
Conclusion
These data confirm that SQV/r is effective and well toler-
ated in ART-naïve patients in the real-life clinical setting.
The results of this observational cohort of treatment with
the 500 mg tablet formulation of SQV are consistent with
high efficacy and tolerability results seen in controlled
studies with SQV/r.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P13 doi:10.1186/1758-2652-11-S1-P13
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P13
© 2008 Knechten et al; licensee BioMed Central Ltd. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of the International AIDS Society 2008, 11(Suppl 1):P13 http://www.jiasociety.org/content/11/S1/P13
Page 2 of 2
(page number not for citation purposes)
Proportion of patients below the detection limit during 48  weeks after start of a SQV/r containing antiretroviral therapy Figure 1
Proportion of patients below the detection limit during 48 
weeks after start of a SQV/r containing antiretroviral ther-
apy.